⌘K

Home/Filings/4/0000950170-24-030228

4//SEC Filing

DiFabio Andrea 4

Accession 0000950170-24-030228

CIK 0001582313other

View on SEC.gov Company Profile

Filed

Mar 11, 8:00 PM ET

Accepted

Mar 12, 6:34 PM ET

Size

14.7 KB

Accession

0000950170-24-030228

Insider Transaction Report

Form 4

Period: 2024-03-11

Xenon Pharmaceuticals Inc.XENE

Chief Legal Officer

Transactions

Award
Stock Option (Right to Buy)
2024-03-11+100,000→ 100,000 total
Exercise: $44.37Exp: 2034-03-10→ Common Shares (100,000 underlying)

Footnotes (1)

[F1]Vesting 25% on January 1, 2025, and 75% vesting thereafter over the course of the next 3 years, in equal amounts, on the last day of each month.

Documents

2 files

Issuer

Xenon Pharmaceuticals Inc.

CIK 0001582313

Entity typeother

Related Parties

1

filerCIK 0001692506

Filing Metadata

Form type: 4
Filed: Mar 11, 8:00 PM ET
Accepted: Mar 12, 6:34 PM ET
Size: 14.7 KB

View on SEC.gov